BASF.Y arrives at its Q1 2026 earnings release tomorrow with a notably charged lending market — cost to borrow has spiked sharply and short interest in the ADR has more than tripled over the past week.
The most striking development in the run-up to Wednesday's print is the sudden jolt in borrow costs. The cost to borrow climbed to 5.46% on Tuesday, from just 1.40% the prior Friday — a near fourfold move in a single session. For context, the rate had been anchored in the 1.25%–1.75% range for the entirety of March and early April. That kind of abrupt repricing almost always reflects a burst of demand for short borrows, not a gradual shift in lender behaviour. Something changed on April 28.
Availability has tightened alongside it. The lending pool is under the most pressure it has seen in weeks, with borrow availability now running near its tightest level of the past year at 90% utilisation. That is meaningfully above where it was through most of March, when the pool was only half-committed. The ADR short position itself has jumped from roughly 23,000 shares in mid-April to over 83,000 — a more than 260% rise in a week, albeit starting from a very low base. The ORTEX short score has moved in the same direction, rising from 38.6 on April 15 to 46.1 on April 28. That is still only a mid-range reading, but the direction of travel over the past ten sessions is consistently upward.
It is worth noting this is the OTC-listed ADR. The absolute share counts are small, and movements can be amplified by thin liquidity rather than representing a coordinated conviction short. Nonetheless, the combination of rising short interest, tightening availability, and a cost-to-borrow spike on the eve of earnings is a pattern worth flagging. The prior two earnings prints delivered first-day losses for the stock: the February 27 full-year results sent the ADR down more than 6%, with a further 10.5% drop over the following five sessions. The March release saw a smaller 3.5% day-one move, followed by a 6.6% five-day recovery. Shorts building into tomorrow may be leaning on that recent track record.
Valuation offers limited support for the bull case at current levels. The EV/EBITDA multiple has eased to 4.5x and has drifted lower over both the past week and month — a modest re-rating lower, but not a dramatic compression. The PE stands at 21.6x, up slightly over the past 30 days. Factor scores paint a mixed picture: the dividend score ranks at the 85th percentile, reflecting BASF's historically generous payout, while EPS surprise ranks at the 83rd percentile — meaning the company has generally beaten estimates. However, the analyst recommendation divergence score ranks at just the 7th percentile, a signal that BASF's stock price and the prevailing analyst consensus are more closely aligned than most. Any analyst data from the OTC listing is too stale to cite, given the latest available ratings predate 2021. The primary view should be anchored to the Frankfurt listing. The stock closed at $15.88 on Tuesday, up 1.8% on the week and 6.3% over the past month, suggesting a degree of optimism has already been priced into the ADR heading into the print.
The most consequential question tomorrow is whether BASF updates its full-year guidance on volumes and margins in the context of ongoing macro uncertainty — that has historically determined the multi-day reaction far more than the quarterly revenue line. Positioning into the release looks genuinely tensioned: shorts have moved, borrow costs have spiked, yet the stock has gained ground on the week. That divergence makes the earnings call the next critical datapoint.
See the live data behind this article on ORTEX.
Open BASF.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
